NeXT Personal®
Molecular Residual Disease Monitoring
Key Facts
Indication
Molecular Residual Disease Monitoring
Phase
Commercial/Validation
Status
Active
Company
About Personalis
Personalis is on a mission to transform cancer management through its industry-leading, ultra-sensitive NeXT Platform for ctDNA detection and MRD monitoring. The company has successfully pivoted from population genomics to focus on the high-growth oncology diagnostics market, securing key partnerships and commercial traction. Its strategy centers on establishing its NeXT Personal® test as the standard for MRD assessment while expanding into adjacent opportunities in therapy selection and immuno-oncology biomarker profiling to drive long-term growth.
View full company profile